Hiroshi Wakui

3.2k total citations
42 papers, 816 citations indexed

About

Hiroshi Wakui is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Epidemiology. According to data from OpenAlex, Hiroshi Wakui has authored 42 papers receiving a total of 816 indexed citations (citations by other indexed papers that have themselves been cited), including 25 papers in Oncology, 23 papers in Pulmonary and Respiratory Medicine and 11 papers in Epidemiology. Recurrent topics in Hiroshi Wakui's work include Lung Cancer Treatments and Mutations (15 papers), Colorectal Cancer Treatments and Studies (8 papers) and Cancer Immunotherapy and Biomarkers (7 papers). Hiroshi Wakui is often cited by papers focused on Lung Cancer Treatments and Mutations (15 papers), Colorectal Cancer Treatments and Studies (8 papers) and Cancer Immunotherapy and Biomarkers (7 papers). Hiroshi Wakui collaborates with scholars based in Japan, United States and Germany. Hiroshi Wakui's co-authors include Hiroshi Nokihara, Noboru Yamamoto, Tomohide Tamura, Yasuhide Yamada, Hirofumi Utsumi, Shinji Nakamichi, Yusuke Okuma, Kazuyoshi Kuwano, Yukio Hosomi and Jun Araya and has published in prestigious journals such as Journal of Clinical Oncology, PLoS ONE and Annals of Oncology.

In The Last Decade

Hiroshi Wakui

40 papers receiving 807 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Hiroshi Wakui Japan 15 412 345 233 103 100 42 816
William Nassib William United States 14 339 0.8× 267 0.8× 227 1.0× 50 0.5× 151 1.5× 44 810
Raimondo Di Liello Italy 13 357 0.9× 228 0.7× 265 1.1× 87 0.8× 51 0.5× 33 738
Sebahat Ocak Belgium 17 175 0.4× 289 0.8× 244 1.0× 67 0.7× 79 0.8× 36 694
Kuo-Ting Chang Taiwan 12 328 0.8× 442 1.3× 213 0.9× 61 0.6× 53 0.5× 22 749
Yu Dong China 14 455 1.1× 389 1.1× 213 0.9× 106 1.0× 65 0.7× 68 913
Dedong Cao China 17 396 1.0× 205 0.6× 270 1.2× 91 0.9× 92 0.9× 50 773
Li‐Han Hsu Taiwan 14 297 0.7× 382 1.1× 248 1.1× 54 0.5× 47 0.5× 30 833
Marisa Cañadas‐Garre Spain 19 256 0.6× 175 0.5× 435 1.9× 101 1.0× 66 0.7× 44 1.0k
Elena Ongaro Italy 15 495 1.2× 304 0.9× 273 1.2× 53 0.5× 44 0.4× 38 878

Countries citing papers authored by Hiroshi Wakui

Since Specialization
Citations

This map shows the geographic impact of Hiroshi Wakui's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Hiroshi Wakui with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Hiroshi Wakui more than expected).

Fields of papers citing papers by Hiroshi Wakui

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Hiroshi Wakui. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Hiroshi Wakui. The network helps show where Hiroshi Wakui may publish in the future.

Co-authorship network of co-authors of Hiroshi Wakui

This figure shows the co-authorship network connecting the top 25 collaborators of Hiroshi Wakui. A scholar is included among the top collaborators of Hiroshi Wakui based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Hiroshi Wakui. Hiroshi Wakui is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
Horinouchi, Hidehito, Shogo Nomura, Satoshi Igawa, et al.. (2023). Reconsidering the Cutoff Value for Sensitive and Refractory Relapses in Extensive-Stage SCLC in the Era of Immunotherapy. Journal of Thoracic Oncology. 19(2). 325–336. 9 indexed citations
3.
Kondo, Tetsuro, Kaoru Kubota, Shinji Nakamichi, et al.. (2023). 1294P A final analysis of a phase II study of durvalumab immediately after completion of chemoradiotherapy in unresectable stage III non–small-cell lung cancer: TORG1937 (DATE study). Annals of Oncology. 34. S746–S747. 1 indexed citations
4.
5.
Okuma, Yusuke, Kaoru Kubota, Mototsugu Shimokawa, et al.. (2023). First-Line Osimertinib for Previously Untreated Patients With NSCLC and Uncommon EGFR Mutations. JAMA Oncology. 10(1). 43–43. 39 indexed citations
6.
Okuma, Yusuke, Kaoru Kubota, Mototsugu Shimokawa, et al.. (2023). Uncommon EGFR mutations conducted with osimertinib in patients with NSCLC (UNICORN): A phase 2 study.. Journal of Clinical Oncology. 41(16_suppl). 9045–9045. 1 indexed citations
7.
Nakamichi, Shinji, Kaoru Kubota, Toshihiro Misumi, et al.. (2022). A phase II study of durvalumab (MEDI4736) immediately after completion of chemoradiotherapy in unresectable stage III non–small cell lung cancer: TORG1937 (DATE study).. Journal of Clinical Oncology. 40(16_suppl). 8536–8536. 4 indexed citations
8.
Hasegawa, Tsukasa, Noriko Yanagitani, Hirofumi Utsumi, et al.. (2019). Association of High Neutrophil-to-Lymphocyte Ratio With Poor Outcomes of Pembrolizumab Therapy in High-PD-L1-expressing Non-small Cell Lung Cancer. Anticancer Research. 39(12). 6851–6857. 27 indexed citations
9.
Numata, Takanori, Katsutoshi Nakayama, Satoko Fujii, et al.. (2018). Risk factors of postoperative pulmonary complications in patients with asthma and COPD. BMC Pulmonary Medicine. 18(1). 4–4. 35 indexed citations
10.
Yamamoto, Noboru, Hiroshi Nokihara, Yasuhide Yamada, et al.. (2016). Phase I study of Nivolumab, an anti-PD-1 antibody, in patients with malignant solid tumors. Investigational New Drugs. 35(2). 207–216. 72 indexed citations
11.
Nishio, Makoto, Atsushi Horiike, Hiroshi Nokihara, et al.. (2015). Phase I study of the anti-MET antibody onartuzumab in patients with solid tumors and MET-positive lung cancer. Investigational New Drugs. 33(3). 632–640. 13 indexed citations
12.
Horinouchi, Hidehito, Noboru Yamamoto, Yutaka Fujiwara, et al.. (2015). Phase I study of ipilimumab in phased combination with paclitaxel and carboplatin in Japanese patients with non-small-cell lung cancer. Investigational New Drugs. 33(4). 881–889. 47 indexed citations
13.
Nokihara, Hiroshi, Yasuhide Yamada, Yutaka Fujiwara, et al.. (2015). Phase I trial of volasertib, a Polo-like kinase inhibitor, in Japanese patients with advanced solid tumors. Investigational New Drugs. 34(1). 66–74. 15 indexed citations
14.
Yoshii, Yutaka, Kenichiro Shimizu, Miyuki Morozumi, et al.. (2014). Multiplex real-time polymerase chain reaction is useful in diagnosing pathogens causing community-acquired pneumonia including atypical bacteria and viruses. European Respiratory Journal. 44(Suppl 58). P4935–P4935. 1 indexed citations
15.
Takasaka, Naoki, Jun Araya, Yusuke Kurita, et al.. (2014). Metformin inhibits TGF-b-induced myofibroblast differentiation through AMPK activation. European Respiratory Journal. 44(Suppl 58). P3854–P3854. 2 indexed citations
16.
Wakui, Hiroshi, Noboru Yamamoto, Satoru Kitazono, et al.. (2014). A phase 1 and dose-finding study of LY2523355 (litronesib), an Eg5 inhibitor, in Japanese patients with advanced solid tumors. Cancer Chemotherapy and Pharmacology. 74(1). 15–23. 39 indexed citations
17.
Nokihara, Hiroshi, Noboru Yamamoto, Shinji Nakamichi, et al.. (2013). A Phase 1 Study of Cabozantinib in Japanese Patients with Advanced Solid Tumors: Anti-Tumor Activity in NSCLC and GIST. Annals of Oncology. 24. ix48–ix48. 8 indexed citations
18.
Yamamoto, Noboru, Hiroshi Nokihara, Yasuhide Yamada, et al.. (2013). A Phase I and Dose-Finding Study of Lenvatinib (E7080) in Japanese Patients with Advanced Solid Tumors. Annals of Oncology. 24. ix48–ix48. 2 indexed citations
19.
Nakamichi, Shinji, Hiroshi Nokihara, Hidenori Mizugaki, et al.. (2013). Phase I Study of LY2523355, an EG5 Inhibitor, in Japanese Patients with Advanced Solid Tumors. Annals of Oncology. 24. ix47–ix47. 1 indexed citations
20.
Tamura, Yoshifumi, Hiroshi Nokihara, Noboru Yamamoto, et al.. (2012). Phase 1 Dose-Escalating Study of BMS-754807 in Japanese Patients with Advanced Solid Tumors. Annals of Oncology. 23. xi111–xi112. 3 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by William Nassib William Breakdown of academic impact, for papers by Raimondo Di Liello Breakdown of academic impact, for papers by Sebahat Ocak Breakdown of academic impact, for papers by Kuo-Ting Chang Breakdown of academic impact, for papers by Yu Dong Breakdown of academic impact, for papers by Dedong Cao Breakdown of academic impact, for papers by Li‐Han Hsu Breakdown of academic impact, for papers by Marisa Cañadas‐Garre Breakdown of academic impact, for papers by Elena Ongaro
Rankless by CCL
2026